MEDSAFE NZ Moves Ahead in 2020

Medsafe NZ has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines.

Since 2015, Medsafe NZ, the  New Zealand Medicines and Medical Devices Safety Authority , has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines, and provide regulation of all therapeutic products.

Whilst we are still waiting for the progression of the Therapeutic Products Bill through parliament, the Guidelines on the Regulation of Therapeutic Products in New Zealand are being modernised in parallel.

While some parts of the guidance were updated in 2018, other mooted changes seem to have been in draft for a long time. In particular, the medical device regulatory update which is still under construction on the  Medsafe New Zealand  website.

The most recent changes have been to Parts 2 (New and Changed Medicines) and 7 (Advertising) of the guidance documents. However, only minor updates were made to Part 2. These sought to clarify and regularise aspects that had previously been discussed with industry, such as acceptance of different dossier formats. The inclusion of some nice decision trees is a welcome addition.

We all had a sigh of relief to see that, while not mandatory, either NeeS (Non-eCTD electronic Submissions) OR eCTD format submissions are now possible. But, let’s not get too excited about this. Medsafe NZ does not have full functionality for eCTDs and therefore, lifecycle management is still a challenge.

Ideally, Medsafe NZ still prefer to see a hyperlinked Table of Contents, rather than an index file. And, we still have one foot in the land of paper submissions with a mandatory hardcopy of Module 1 to be provided together with two electronic copies of the full dossier (Modules 1-5).  Acceptable electronic media is limited to CDs and DVDs only.

Part 7 advertising guidance had a major update and is very clear and readable in terms of what is allowable for advertising of medical devices, medicines (prescription, OTC, restricted in New Zealand. This includes internet, mail order, point of sale and direct marketing advertisements as well as communications to health professionals.

Of note, and something that often catches out Sponsors in their website advertising, is that testimonials must not be used.

More recent articles

  • 2024 A Year in Review

    2024 A Year in Review

    As we approach the close of 2024, it’s essential to reflect on our achievements, growth, and the incredible progress we’ve made together. This year has been transformative, marked by milestones that position the Adjutor Healthcare Group for even greater success in 2025. As we look forward, we remain committed to innovation, collaboration, and delivering exceptional…

  • Advertising and Promotional Material Review for Therapeutic Goods in Australia

    Advertising and Promotional Material Review for Therapeutic Goods in Australia

    Navigating advertising compliance for therapeutic goods in Australia can feel like walking a tightrope. With multiple advertising laws enforced by different regulators, businesses must tread carefully to avoid penalties or legal complications.

  • Understanding TGA GMP Clearance

    Understanding TGA GMP Clearance

    Understanding TGA Good Manufacturing Practice (GMP) requirements for Australian Regulatory Submissions Good Manufacturing Practice (GMP) is vital in ensuring the quality, safety, and efficacy of the therapeutic goods for human use (including sunscreens). In Australia, the Therapeutic Goods Administration (TGA) oversees the implementation and enforcement of GMP standards to uphold the integrity of the pharmaceutical…